Real-world outcomes of molecular targeted agents for patients with hepatocellular carcinoma over 80 years old

被引:2
作者
Sato, Rui [1 ]
Moriguchi, Michihisa [2 ]
Iwai, Kenji [1 ]
Tsuchiya, Satoshi [1 ]
Seko, Yuya [2 ]
Takahashi, Aya [2 ]
Kobayashi, Kazufumi [3 ]
Ogasawara, Sadahisa [3 ]
Watanabe, Shunji [4 ]
Morimoto, Naoki [4 ]
Kato, Naoya [3 ]
Itoh, Yoshito [2 ]
Aramaki, Takeshi [1 ]
机构
[1] Shizuoka Canc Ctr, Div Intervent Radiol, 1007 Shimonagakubo, Nagaizumi, Shizuoka 4118777, Japan
[2] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Mol Gastroenterol & Hepatol, Kyoto, Japan
[3] Chiva Univ, Grad Sch Med, Dept Gastroenterol, Chiba, Japan
[4] Jichi Med Univ, Dept Med, Div Gastroenterol, Shimotsuke, Tochigi, Japan
关键词
discontinuation due to adverse events; elderly patients with HCC; lenvatinib; molecular targeted agent; sorafenib; PHASE-III; DOUBLE-BLIND; 1ST-LINE TREATMENT; SORAFENIB; PLACEBO; LENVATINIB; THERAPY; MULTICENTER; BRIVANIB;
D O I
10.1111/hepr.13818
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim There is insufficient evidence regarding the safety and efficacy of molecular targeted agents (MTAs) for elderly patients with hepatocellular carcinoma (HCC), who are likely to be vulnerable to adverse events (AEs) of therapy. The aim of this study was to compare sorafenib and lenvatinib use in elderly patients with HCC from the viewpoint of overall survival (OS) and rate of AE-induced MTA discontinuation. Methods This retrospective study included patients with HCC over 80 years old who received first-line molecular targeted therapy (MTT) at four hospitals between June 2009 and September 2019. They were divided into three groups according to the era and type of first-line MTA: E1-Sora (sorafenib, between 2009 and 2016), E2-Sora (sorafenib, between 2017 and 2019), and E2-Len (lenvatinib, between 2017 and 2019). Results The study included 173 patients (E1-Sora, n = 79; E2-Sora, n = 50; E2-Len, n = 44) with a median age of 81.9 years (range, 80-93 years). Median OS was 15.1 months in the entire cohort (E1-Sora, 12.7 months; E2-Sora, 20.5 months; E2-Len, 10.3 months). The rate of treatment discontinuation due to AEs was high in the entire cohort, especially in E1-Sora and E2-Len (49.4% in E1-Sora, 28.0% in E2-Sora, and 54.6% in E2-Len, p = 0.0753). More E2-Sora patients received subsequent MTT than E2-Len patients (E2-Sora, 50%; E2-Len, 28.6%; p = 0.0111). Conclusion Both sorafenib and lenvatinib were effective and feasible for elderly patients with HCC. In terms of discontinuation due to AEs and subsequent MTT, sorafenib might be more desirable for elderly patients with HCC over 80 years.
引用
收藏
页码:859 / 871
页数:13
相关论文
共 33 条
[31]   Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial [J].
Zhu, Andrew X. ;
Park, Joon Oh ;
Ryoo, Baek-Yeol ;
Yen, Chia-Jui ;
Poon, Ronnie ;
Pastorelli, Davide ;
Blanc, Jean-Frederic ;
Chung, Hyun Cheol ;
Baron, Ari D. ;
Pfiffer, Tulio Eduardo Flesch ;
Okusaka, Takuji ;
Kubackova, Katerina ;
Trojan, Jorg ;
Sastre, Javier ;
Chau, Ian ;
Chang, Shao-Chun ;
Abada, Paolo B. ;
Yang, Ling ;
Schwartz, Jonathan D. ;
Kudo, Masatoshi .
LANCET ONCOLOGY, 2015, 16 (07) :859-870
[32]   SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma [J].
Zhu, Andrew X. ;
Rosmorduc, Olivier ;
Evans, T. R. Jeffry ;
Ross, Paul J. ;
Santoro, Armando ;
Carrilho, Flair Jose ;
Bruix, Jordi ;
Qin, Shukui ;
Thuluvath, Paul J. ;
Llovet, Josep M. ;
Leberre, Marie-Aude ;
Jensen, Markus ;
Meinhardt, Gerold ;
Kang, Yoon-Koo .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (06) :559-566
[33]   Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib The EVOLVE-1 Randomized Clinical Trial [J].
Zhu, Andrew X. ;
Kudo, Masatoshi ;
Assenat, Eric ;
Cattan, Stephane ;
Kang, Yoon-Koo ;
Lim, Ho Yeong ;
Poon, Ronnie T. P. ;
Blanc, Jean-Frederic ;
Vogel, Arndt ;
Chen, Chao-Long ;
Dorval, Etienne ;
Peck-Radosavljevic, Markus ;
Santoro, Armando ;
Daniele, Bruno ;
Furuse, Junji ;
Jappe, Annette ;
Perraud, Kevin ;
Anak, Oezlem ;
Sellami, Dalila B. ;
Chen, Li-Tzong .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 312 (01) :57-67